Encouraging Clinical Results with In Situ Conversion Therapy NXL-004 for Malignant Glioma Reported
In the patient receiving intratumoral injection, a clear therapeutic response was observed, with target lesion shrinkage exceeding 90%. In one patient treated with tumor resection followed by intracavitary injection of NXL-004, postoperative imaging demonstrated progressive tumor reduction leading to complete radiographic disappearance, achieving a complete response (CR). The results demonstrate that NXL-004 exhibits both a favorable safety profile and promising clinical efficacy, validating the feasibility and therapeutic potential of in situ conversion therapy in the treatment of glioma.
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines